Gilead Sciences Inc (GILD)
88.40
-3.71
(-4.03%)
USD |
NASDAQ |
Nov 15, 16:00
88.59
+0.19
(+0.21%)
After-Hours: 20:00
Gilead Sciences Research and Development Expense (TTM): 8.104B for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 8.104B |
| June 30, 2024 | 8.166B |
| March 31, 2024 | 8.222B |
| December 31, 2023 | 5.719B |
| September 30, 2023 | 3.159B |
| June 30, 2023 | 2.851B |
| March 31, 2023 | 2.546B |
| December 31, 2022 | 4.977B |
| September 30, 2022 | 7.487B |
| June 30, 2022 | 7.439B |
| March 31, 2022 | 7.429B |
| December 31, 2021 | 4.606B |
| September 30, 2021 | 4.826B |
| June 30, 2021 | 4.883B |
| March 31, 2021 | 5.09B |
| December 31, 2020 | 5.039B |
| September 30, 2020 | 4.56B |
| June 30, 2020 | 4.432B |
| March 31, 2020 | 4.128B |
| December 31, 2019 | 4.181B |
| September 30, 2019 | 3.934B |
| June 30, 2019 | 3.843B |
| March 31, 2019 | 4.04B |
| December 31, 2018 | 3.92B |
| September 30, 2018 | 4.218B |
| Date | Value |
|---|---|
| June 30, 2018 | 4.068B |
| March 31, 2018 | 3.74B |
| December 31, 2017 | 3.734B |
| September 30, 2017 | 3.792B |
| June 30, 2017 | 4.144B |
| March 31, 2017 | 4.764B |
| December 31, 2016 | 5.098B |
| September 30, 2016 | 4.647B |
| June 30, 2016 | 4.249B |
| March 31, 2016 | 3.583B |
| December 31, 2015 | 3.014B |
| September 30, 2015 | 3.302B |
| June 30, 2015 | 3.189B |
| March 31, 2015 | 2.955B |
| December 31, 2014 | 2.854B |
| September 30, 2014 | 2.361B |
| June 30, 2014 | 2.277B |
| March 31, 2014 | 2.217B |
| December 31, 2013 | 2.12B |
| September 30, 2013 | 2.007B |
| June 30, 2013 | 1.927B |
| March 31, 2013 | 1.799B |
| December 31, 2012 | 1.76B |
| September 30, 2012 | 1.723B |
| June 30, 2012 | 1.547B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
2.546B
Minimum
Mar 2023
8.222B
Maximum
Mar 2024
5.392B
Average
4.93B
Median
Research and Development Expense (TTM) Benchmarks
| Eli Lilly and Co | 10.53B |
| Merck & Co Inc | 22.98B |
| Pfizer Inc | 10.60B |
| Vertex Pharmaceuticals Inc | 3.456B |
| Amgen Inc | 5.774B |